100 Microns and 170 Microns Segment to Dominate North America Blood Filter Market during 2019–2028
According to The Insight Partners market research study on “North America Blood Filter Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product, Material, Application, and End User,” is expected to reach US$ 2,09,486.60 thousand by 2028 from US$ 1,56,782.04 thousand in 2021. The market is estimated to grow at a CAGR of 4.2% from 2021 to 2028. Rapid increase in burden of chronic diseases is the major factor driving the growth of the North America blood filter market. However, product recalls may hinder the growth of North America blood filter market. The report provides trends prevailing in the North America blood filter market along with the drivers and restraints pertaining to the market growth.
Cytokine storm occurring in COVID-19 patients causes significant organ damage, and if the condition worsens it may lead to the death of the patient. For the first time in the United States, when patients show discomfort, doctors replace the usual filter on a kidney dialysis machine with a filter that traps these tiny proteins to avoid destruction. The approved product reduces the number of cytokines and other inflammatory mediators, i.e., small active proteins in the bloodstream that control a cell's immune response by filtering the blood and returning the filtered blood to the patient. The ABO blood group characteristic reflects polymorphisms within the ABO gene. This gene is linked to several other traits, including COVID-19 morbidity and mortality risk factors. For example, genome-wide association studies have variants within ABO with angiotensin-converting enzyme activity, red blood cell count, hematocrit, hemoglobin concentration, von Willebrand factor, myocardial infarction, ischemic stroke, type 2 diabetes, coronary artery disease, and venous thromboembolism. These conditions are also relevant for COVID-19. of the number of blood donations drastically reduced in North American countries due to social restrictions and the possibility of disease transmission in the early stages of the outbreak. Washington and other areas of the US experienced a substantial temporary drop in blood supply during the early stages of the pandemic. Hospitals and blood donation centers proactively implemented blood conservation strategies and made efforts to encourage blood donations. Blood conservation plans may have led to a reduction in transfusions. In early 2020, the cancellation or delays in elective surgeries in hospitals to prioritize COVID-19 patients also resulted in a significant decrease in blood requirements.
The North America blood filter market is segmented into product, application, material, end user, and country. The North America blood filter market, by product, is segmented into 40 Microns and 70 Microns, 100 Microns and 170 Microns, and others. The 100 microns to 170 microns segment held the largest share of the market in 2021. The North America blood filter market, by material, is segmented into polycarbonate, polyester, ABS, and others. The polyester segment held the largest share of the market in 2021. The North America blood filter market, by application, is segmented into blood processing and blood transfusion. The blood transfusion segment held the largest share of the market in 2021. On the basis of blood transfusion, the market is further segmented into whole blood, red cell, and plasma and platelet filtration. The plasma and platelet filtration segment accounts for largest market share in the 2021. Based on end user, the North America blood filter market is segmented blood banks, hospitals, and others. The blood banks segment held the largest share of the market in 2021. Similarly, based on country, the market is bifurcated into US, Canada, and Mexico. The US contributed a substantial share in 2021.
Asahi Kasei Corporation; Fresenius Kabi AG; Haemonetics Corporation; KANEKA CORPORATION; Kawasumi laboratories. Inc.; Macopharma; Sefar AG; and Shandong Zhongbaokang Medical Implements Co., Ltd are among the leading companies in the North America Blood Filter Market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2020, Kaneka Corporation developed an Adsorption Type Blood Purification Device (RheocarnaTM) that treats a severe form of arteriosclerosis obliterans (referred to below as ASO)*1 with lower limb ulcers and received FDA approval for its manufacture and sale.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com